Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BMEA Biomea Fusion, Inc.

Pre-Mkt 09-21 04:13:59 EDT

1.83

+0.04

+2.23%

High1.93	Low1.77	Vol1.63M
Open1.79	D1 Closing1.79	Amplitude8.93%
Mkt Cap132.31M	Tradable Cap122.62M	Total Shares72.30M
T/O3.01M	T/O Rate2.43%	Tradable Shares67.01M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BMEA","market":"US","secType":"STK","nameCN":"Biomea Fusion, Inc.","latestPrice":1.83,"timestamp":1789761600000,"preClose":1.79,"halted":0,"volume":1630910,"delay":0,"changeRate":0.022346368715083817,"floatShares":67007373,"shares":72299440,"eps":-0.471065,"marketStatus":"Pre-Mkt","change":0.04,"latestTime":"09-21 04:13:59 EDT","open":1.79,"high":1.93,"low":1.7701,"amount":3013639.0432969998,"amplitude":0.08933,"askPrice":1.82,"askSize":139,"bidPrice":1.61,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.471065,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789997400000},"marketStatusCode":1,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":1.83,"postHourTrading":{"tag":"盘后","latestPrice":1.85,"preClose":1.83,"latestTime":"19:54 EDT","volume":23751,"amount":43527.3585,"timestamp":1789775675793,"change":0.02,"changeRate":0.010929,"amplitude":0.016776},"volumeRatio":1.1096657972482604,"impliedVol":1.1259,"impliedVolPercentile":0.572},"requestUrl":"/m/hq/s/BMEA/tweets","defaultTab":"tweets","newsList":[{"id":"2664779048","title":"Biomea Fusion to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664779048","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664779048?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:00","pubTimestamp":1788436800,"startTime":"0","endTime":"0","summary":"SAN CARLOS, Calif., Sept.  03, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/03/3355833/0/en/biomea-fusion-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4539","BK4139","BMEA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663972420","title":"Biomea Fusion Completes Key Phase 2 Trial in Type 1 Diabetes: What Investors Should Watch Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2663972420","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663972420?lang=en_us&edition=fundamental","pubTime":"2026-08-29 00:30","pubTimestamp":1787934613,"startTime":"0","endTime":"0","summary":"Biomea Fusion Inc ($BMEA) announced an update on their ongoing clinical study. Biomea Fusion Inc. has completed a mid-stage study of BMF-219 in adu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biomea-fusion-completes-key-phase-2-trial-in-type-1-diabetes-what-investors-should-watch-next?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biomea-fusion-completes-key-phase-2-trial-in-type-1-diabetes-what-investors-should-watch-next?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","BK4539","ISBC","BK4585","BK4139","BMEA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662203426","title":"Biomea Shares Rise After Completing Enrollment in Diabetes Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2662203426","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662203426?lang=en_us&edition=fundamental","pubTime":"2026-08-25 02:47","pubTimestamp":1787597276,"startTime":"0","endTime":"0","summary":"Biomea Fusion  shares rose over 14% in Monday trading after the firm said it has completed enrollment in a phase 2 trial of icovamenib in insulin-deficient Type 2 diabetes patients.The clinical-stage firm said topline 26-week primary endpoint data from the COVALENT-211 trial is expected in Q1 of 2027.Biomea also said COVALENT-212 mid-stage trial enrollment is still ongoing, with topline 26-week primary endpoint data anticipated in Q2 of 2027.Price: 1.57, Change: +0.20, Percent Change: +14.60","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BMEA","BK4139","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271007","title":"Unusually active option classes on open August 24th","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271007","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271007?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:40","pubTimestamp":1787578821,"startTime":"0","endTime":"0","summary":"Unusual total active option classes on open include: Biomea Fusion (BMEA), Vale (VALE), 21Vianet (VNET), Tractor Supply (TSCO), Humana (HUM), Pindu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-august-24th-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unusually-active-option-classes-on-open-august-24th-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0572108347.SGD","LU0072463663.USD","TSCO","LU0612318385.USD","LU0417517546.SGD","LU0531970944.HKD","IE00B3M56506.USD","IE00B1B80R65.USD","LU1941712348.USD","HUM","BK4533","LU0254981946.USD","LU0256863811.USD","SG9999014005.SGD","LU0265266980.USD","BK4531","BMEA","BK4154","LU1046422090.SGD","LU0348723411.USD","LU0256859116.SGD","BK4585","LU0265267285.USD","VALG","VALE","LU0320765489.SGD","LU0390134368.USD","LU0075056555.USD","LU0823046494.USD","LU0788109048.HKD","BK4516","BK4548","LU1941712264.USD","SLX","VNET","IHF","LU0106259046.USD","BK4200","LU0266013472.USD","LU0788109121.HKD","LU1917777945.USD","SG9999014013.SGD","LU0070302665.USD","LU0211331839.USD","LU0238689110.USD","LU1974910355.USD","BK4607","FXH","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275857","title":"Biomea Fusion completes enrollment in COVALENT-211 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275857","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275857?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:15","pubTimestamp":1787570122,"startTime":"0","endTime":"0","summary":"Biomea Fusion (BMEA) announced the completion of enrollment in COVALENT-211, a randomized, double-blinded, placebo-controlled Phase II clinical tri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biomea-fusion-completes-enrollment-in-covalent-211-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biomea-fusion-completes-enrollment-in-covalent-211-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BMEA","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661733312","title":"Biomea Fusion, - Topline 26-Week Primary Endpoint Data from Covalent-211 Expected in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2661733312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661733312?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA4VMQST:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BMEA","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661361273","title":"Biomea Fusion Announces Completion of Enrollment in Covalent-211 Phase Ii Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2661361273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661361273?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA4VMQST:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","BK4585","BMEA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660359488","title":"Biomea Fusion doses first patient in OPAL study","url":"https://stock-news.laohu8.com/highlight/detail?id=2660359488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660359488?lang=en_us&edition=fundamental","pubTime":"2026-08-17 15:38","pubTimestamp":1786952287,"startTime":"0","endTime":"0","summary":"Biomea Fusion (BMEA) announced that the first participant has been dosed in a new arm of the ongoing platform research study, Investigating and Opt...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biomea-fusion-doses-first-patient-in-opal-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biomea-fusion-doses-first-patient-in-opal-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMEA","BK4539","BK4585","BK4139","OPAL","BK4138"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659168244","title":"Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB) and Biomea Fusion (BMEA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659168244","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659168244?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:10","pubTimestamp":1786630208,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Connect Biopharma Holdings (CNTB) and Biomea Fusion ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-connect-biopharma-holdings-cntb-and-biomea-fusion-bmea-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-connect-biopharma-holdings-cntb-and-biomea-fusion-bmea-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","HCSG","BK4139","BK4588","CNTB","BK4539","BK4137","LABU","BK4585","BK4581","LU0029874061.USD","LU0128526141.USD","BMEA","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659156597","title":"Biomea Fusion Doses First Patient in OPAL Trial of Icovamenib Plus Semaglutide for Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2659156597","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659156597?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:03","pubTimestamp":1786619009,"startTime":"0","endTime":"0","summary":"Biomea Fusion doses first patient in OPAL trial of icovamenib plus semaglutide for obesityBiomea Fusion dosed the first participant in a new OPAL trial arm testing icovamenib with low-dose semaglutide","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLVnzpX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BN0W2T93.GBP","BK4585","LU0314104364.USD","BK4539","NDAQ","SG9999014039.USD","LU2095319765.USD","LU2210149790.SGD","BMEA","BCDF","BK4139","IE00B3QW5Z07.USD","SG9999014021.USD","SG9999014005.SGD","BK4112","IE00BKPKM429.USD","IE00BN0W2W23.USD","LU2210150020.SGD","IE00B64PRP62.GBP","BK4588","IE00BN0W2V16.EUR","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659155084","title":"Biomea Fusion Announces First Patient Dosed in Opal Study Evaluating Icovamenib in Combination with Semaglutide in Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2659155084","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659155084?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:00","pubTimestamp":1786618802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA77KTHB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BMEA","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658994062","title":"Citi adds ‘upside 90-day catalyst watch’ on Biomea into GLP-1 data","url":"https://stock-news.laohu8.com/highlight/detail?id=2658994062","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658994062?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:00","pubTimestamp":1786446032,"startTime":"0","endTime":"0","summary":"Citi analyst Yigal Nochomovitz added an “upside 90-day catalyst watch” on Biomea Fusion (BMEA) while keeping a Buy rating on the shares with a $7 p...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citi-adds-upside-90-day-catalyst-watch-on-biomea-into-glp-1-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citi-adds-upside-90-day-catalyst-watch-on-biomea-into-glp-1-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLP","BK4139","BK4539","BK4585","BK4144","JDOC","BK4590","BMEA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657965016","title":"Vaxart Q2 Revenue Falls on Lower Government Contract Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2657965016","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657965016?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:19","pubTimestamp":1786047545,"startTime":"0","endTime":"0","summary":"Vaxart Q2 revenue falls on lower government contract incomeOverviewUS oral vaccine developer's Q2 revenue fell yr/yr, mainly on lower government contract revenueNet loss for Q2 narrowed from prior yea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431FN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VXRT","BK4585","BNTX","BK4548","BK4539","BK4568","BMEA","BK4588","BK4535","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657165235","title":"Biomea Fusion price target lowered to $7 from $9 at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2657165235","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657165235?lang=en_us&edition=fundamental","pubTime":"2026-08-07 03:25","pubTimestamp":1786044343,"startTime":"0","endTime":"0","summary":"Citizens lowered the firm’s price target on Biomea Fusion (BMEA) to $7 from $9 and keeps an Outperform rating on the shares. The firm noted that da...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biomea-fusion-price-target-lowered-to-7-from-9-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biomea-fusion-price-target-lowered-to-7-from-9-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMEA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663442","title":"Biomea Fusion (BMEA) Gets a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663442","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657663442?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:57","pubTimestamp":1786021056,"startTime":"0","endTime":"0","summary":"In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Biomea Fusion, with a price target of $9.00. According to T...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/biomea-fusion-bmea-gets-a-buy-from-oppenheimer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/biomea-fusion-bmea-gets-a-buy-from-oppenheimer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4127","BK4585","BK4539","OPY","BMEA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657350856","title":"PepGen Q2 Net Loss Narrows as Expenses Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2657350856","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657350856?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:52","pubTimestamp":1786017130,"startTime":"0","endTime":"0","summary":"PepGen Q2 net loss narrows as expenses fallOverviewBiotechnology company's Q2 net loss narrowed yr/yr as operating expenses declinedCompany ended Q2 with $117.2 mln in cash, sufficient to fund operati","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430LC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DSGN","BK4505","BK4139","PEPG","BK4585","BK4539","TRDA","BMEA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657949633","title":"Amylyx Pharmaceuticals Q2 Posts Higher than Expected Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657949633","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657949633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:26","pubTimestamp":1786015601,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals Q2 posts higher than expected lossOverviewBiopharma firm's Q2 net loss and loss per share missed analyst expectationsCompany completed final study visit in pivotal Phase 3 LUCID","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430HM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA","INDV","MNKD","BK4585","BK4584","BK4539","AMLX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657687470","title":"Analyst Maintains Buy Rating on Biomea Fusion as Metabolic Pipeline Advances and $4 Price Target Remains Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2657687470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657687470?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:37","pubTimestamp":1786012626,"startTime":"0","endTime":"0","summary":"Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Biomea Fusion, retaining the price target of $4.00. Joseph Pantginis has giv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-rating-on-biomea-fusion-as-metabolic-pipeline-advances-and-4-price-target-remains-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-rating-on-biomea-fusion-as-metabolic-pipeline-advances-and-4-price-target-remains-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMEA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657577129","title":"Biomea Fusion, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657577129","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657577129?lang=en_us&edition=fundamental","pubTime":"2026-08-06 08:25","pubTimestamp":1785975932,"startTime":"0","endTime":"0","summary":"Biomea Fusion, Inc. reports results for the quarter ended June 30 - Earnings SummaryBiomea Fusion, Inc.BMEA.OQreported a quarterly adjusted loss of 12 cents per share for the quarter ended June 30, hi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N443013:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA","BK4139","BK4539","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571265","title":"Biomea Fusion Q2 EPS $(0.12) Beats $(0.22) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571265","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571265?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:11","pubTimestamp":1785967902,"startTime":"0","endTime":"0","summary":"Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.22) by 45.45 percent. This is a 76.47 percent increase over losses of $(0.51) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60979036/biomea-fusion-q2-eps-0-12-beats-0-22-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Biomea Fusion Q2 EPS $(0.12) Beats $(0.22) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biomeafusion.com","stockEarnings":[{"period":"1week","weight":0.0517},{"period":"1month","weight":0.3165},{"period":"3month","weight":0.5508},{"period":"6month","weight":0.6053},{"period":"1year","weight":-0.1202},{"period":"ytd","weight":0.4758}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0096},{"period":"3month","weight":0.02},{"period":"6month","weight":0.1744},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.117}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.06322},{"month":2,"riseRate":0.4,"avgChangeRate":0.025302},{"month":3,"riseRate":0.4,"avgChangeRate":0.163799},{"month":4,"riseRate":0,"avgChangeRate":-0.156763},{"month":5,"riseRate":0.666667,"avgChangeRate":0.113922},{"month":6,"riseRate":0.5,"avgChangeRate":0.078877},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.050106},{"month":8,"riseRate":0.833333,"avgChangeRate":0.137883},{"month":9,"riseRate":0.5,"avgChangeRate":0.004539},{"month":10,"riseRate":0.2,"avgChangeRate":-0.126858},{"month":11,"riseRate":0.4,"avgChangeRate":-0.034764},{"month":12,"riseRate":0.4,"avgChangeRate":-0.114655}],"exchange":"NASDAQ","name":"Biomea Fusion, Inc.","nameEN":"Biomea Fusion, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biomea Fusion, Inc.(BMEA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biomea Fusion, Inc.,BMEA,Biomea Fusion, Inc.股票,Biomea Fusion, Inc.股票老虎,Biomea Fusion, Inc.股票老虎国际,Biomea Fusion, Inc.行情,Biomea Fusion, Inc.股票行情,Biomea Fusion, Inc.股价,Biomea Fusion, Inc.股市,Biomea Fusion, Inc.股票价格,Biomea Fusion, Inc.股票交易,Biomea Fusion, Inc.股票购买,Biomea Fusion, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biomea Fusion, Inc.(BMEA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction